Kathie M. Bishop, Ph.D.

Chief Scientific Officer

Kathie M. Bishop, Ph.D., was appointed as our Chief Scientific Officer in November 2016 and joined the company beginning in January 2017. Dr. Bishop is a neuroscientist with more than fifteen years of pharmaceutical development experience. Prior to Otonomy she served as Chief Scientific Officer of Tioga Pharmaceuticals from May 2015 to November 2016. From September 2009 to April 2015, she served in various product development management roles at Ionis Pharmaceuticals including Vice President, Clinical Development. At Ionis, she led translational research and development of multiple preclinical and clinical programs in the neurology franchise including SPINRAZA™ (nusinersen), an approved treatment for patients with spinal muscular atrophy that was awarded the Prix Galien USA Award for the Best Biotechnology Product in 2017. From August 2001 to September 2009, Dr. Bishop served in research and development leadership roles at Ceregene, a company focused on the development of gene therapy products for the treatment of neurodegenerative disorders and retinal diseases. From September 1997 to July 2001, she worked as a post-doctoral fellow in the Molecular Neurobiology Lab at the Salk Institute for Biological Studies. Dr. Bishop obtained a Ph.D. in Neuroscience from the University of Alberta and Bachelor’s degrees in Cell Biology and Genetics from the University of British Columbia and Psychology from Simon Fraser University.